LONDON (ShareCast) - (Sharecast News) - 4basebio announced a significant contract through a competitive tender process on Friday, to provide research and GMP-grade synthetic DNA for the advancement of RNA therapeutics and vaccines at CPI's RNA Centre of Excellence.
The AIM-traded firm said the focus of the tender process was on manufacturing plasmid and synthetic DNA templates, with 4basebio emerging as the successful supplier.

The partnership would see 4basebio meeting CPI's DNA requirements for the development and scaling up of innovative RNA therapeutics.

Using its synthetic 'opDNA' templates, 4basebio said it offered a number of advantages crucial for mRNA production, including superior transcriptional yields, eliminating the need for enzymatic linearisation, and offering reduced turnaround time, enhanced safety, and cost-effectiveness.

"We are delighted to have met CPI's RNA Centre of Excellence criteria for the supply of DNA templates," said chief executive and chief scientific officer Heikki Lanckriet.

"Our growing client base recognises the benefits of opDNA in mRNA production for clinical application and it is rewarding to see this potential recognised by CPI as well.

"We aim to support and accelerate the development of RNA medicines for the organisations that CPI is working with."

At 1101 GMT, shares in 4basebio were up 4.29% at 850p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE